Lexicon Pharma (LXRX) Reports In-Line Q3 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.24 -2.18%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
RIBT, INLB, FTXP, More
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
RIBT, INLB, FTXP, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $2.06 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- BetterLife Pharma names Charles Duncan as director and audit chair
- BofA turns S&P 500 signals from red to yellow: What to buy now
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
